Loading...
XNAS
CAPR
Market cap1.02bUSD
Jul 09, Last price  
22.50USD
1D
1.12%
1Q
-27.88%
Jan 2017
-15.41%
IPO
-95.00%
Name

Capricor Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:CAPR chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
24.45%
Rev. gr., 5y
85.83%
Revenues
0k
-100.00%
380,835101,4000001,355,000195,500503,2334,167,0003,776,0003,190,0002,666,0001,671,0001,005,028310,250244,8982,551,46925,178,06622,270,4650
Net income
-105m
L+159.58%
-2,581,972-10,303,000-13,132,000-7,872,000-6,031,000-4,885,000-1,893,000-8,892,000-6,217,000-12,857,000-18,807,0002,431,000-15,191,000-7,641,817-13,657,028-20,022,520-29,019,532-22,287,542-40,467,186-105,043,946
CFO
-70m
L+74.55%
-55,597-5,372,617-10,640,044-5,795,494-4,318,264-4,649,292-2,186,681-6,144,000958,562-10,817,286-15,801,620-14,230,879-13,862,441-6,821,501-10,054,810-16,809,3244,916,637-25,596,545-39,995,742-69,811,261

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
URL
https://capricor.com/
IPO date
Jun 04, 2002
Employees
74
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT